<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>HIV on VitaminDWiki</title><link>/tags/hiv.html</link><description>Recent content in HIV on VitaminDWiki</description><generator>Hugo</generator><language>en-us</language><lastBuildDate>Sat, 17 Dec 2016 00:00:00 +0000</lastBuildDate><atom:link href="/tags/hiv/index.xml" rel="self" type="application/rss+xml"/><item><title>8 times less bacteria in blood of HIV patients if Vitamin D levels greater than 30 ng</title><link>/posts/8-times-less-bacteria-in-blood-of-hiv-patients-if-vitamin-d-levels-greater-than-30-ng.html</link><pubDate>Sat, 17 Dec 2016 00:00:00 +0000</pubDate><guid>/posts/8-times-less-bacteria-in-blood-of-hiv-patients-if-vitamin-d-levels-greater-than-30-ng.html</guid><description>&lt;h4 id="optimal-vitamin-d-plasma-levels-are-associated-with-lower-bacterial-dna-translocation-in-hivhepatitis-c-virus-coinfected-patients">Optimal vitamin D plasma levels are associated with lower bacterial DNA translocation in HIV/hepatitis c virus coinfected patients.&lt;/h4>
&lt;p>AIDS. 2016 Apr 24;30(7):1069-74. &lt;a href="https://doi.org/10.1097/QAD.0000000000001007.">doi: 10.1097/QAD.0000000000001007.&lt;/a>&lt;/p>
&lt;p>García-Álvarez M1, Berenguer J, Jiménez-Sousa MÁ, Vázquez-Morón S, Carrero A, Gutiérrez-Rivas M, Aldámiz-Echevarría T, López JC, García-Broncano P, Resino S.&lt;/p>
&lt;p>1aUnit of Viral Infection and Immunity, National Centre of Microbiology. Instituto de Salud Carlos III, Majadahonda,bInfectious Diseases-HIV Unit, Hospital General Universitario &amp;lsquo;Gregorio Marañón&amp;rsquo;cHealth Research Institute &amp;lsquo;Gregorio Marañón&amp;rsquo;, Madrid, Spain.&lt;/p></description></item><item><title>Animal study: vitamin D as an adjunct therapy for the treatment of Pneumocystis pneumonia</title><link>/posts/animal-study-vitamin-d-as-an-adjunct-therapy-for-the-treatment-of-pneumocystis-pneumonia.html</link><pubDate>Mon, 04 Jan 2016 00:00:00 +0000</pubDate><guid>/posts/animal-study-vitamin-d-as-an-adjunct-therapy-for-the-treatment-of-pneumocystis-pneumonia.html</guid><description>&lt;h3 id="animal-study-vitamin-d-as-an-adjunct-therapy-for-the-treatment-of-pneumocystis-pneumoniahttpwwwvitamindcouncilorgbloganimal-study-vitamin-d-as-an-adjunct-therapy-for-the-treatment-of-pneumocystis-pneumonia-vitamin-d-council">&lt;a href="http://www.vitamindcouncil.org/blog/animal-study-vitamin-d-as-an-adjunct-therapy-for-the-treatment-of-pneumocystis-pneumonia/">Animal study: vitamin D as an adjunct therapy for the treatment of Pneumocystis pneumonia&lt;/a> Vitamin D Council&lt;/h3>
&lt;ul>
&lt;li>
&lt;p>This disease frequently affects those who suffer from acquired immune deficiency syndrome (AIDS), etc.&lt;/p>
&lt;/li>
&lt;li>
&lt;p>In 2014, the incidence of PcP in the United States was 9% among hospitalized AIDS patients&lt;/p>
&lt;/li>
&lt;li>
&lt;p>The mortality rate for PcP is between 5-40% if treated and 100% if untreated.&lt;/p>
&lt;/li>
&lt;li>
&lt;p>300IU/kg/day of vitamin D to mice helped treatment&lt;/p>
&lt;/li>
&lt;/ul></description></item><item><title>Cats with feline HIV and hospitalized cats have low levels of vitamin D</title><link>/posts/cats-with-feline-hiv-and-hospitalized-cats-have-low-levels-of-vitamin-d.html</link><pubDate>Sat, 28 Nov 2015 00:00:00 +0000</pubDate><guid>/posts/cats-with-feline-hiv-and-hospitalized-cats-have-low-levels-of-vitamin-d.html</guid><description>&lt;h4 id="vitamin-d-status-in-cats-with-feline-immunodeficiency-virus">Vitamin D status in cats with feline immunodeficiency virus&lt;/h4>
&lt;p>Veterinary Medicine and Science, Volume 1, Issue 2, pages 72–78, Oct2015&lt;/p>
&lt;p>Helen F. Titmarsh1,*, Stephanie M. Lalor1, Severine Tasker2, Emily N. Barker2, Jacqueline Berry3, Danielle Gunn-More1 and Richard J Mellanby1&lt;/p>
&lt;img src="https://d378j1rmrlek7x.cloudfront.net/attachments/jpeg/feline-hiv.jpg" alt="image">
&lt;p>Feline immunodeficiency virus (FIV) is a lentivirus that can lead to a syndrome of acquired immune dysfunction. Infected cats often remain asymptomatic for several years before immune dysfunction leads to an increased risk for the development of systemic diseases, neoplasia and opportunistic infections. FIV is structurally related to human immunodeficiency virus (HIV) and the pathogenesis of FIV-related disease is similar to that seen in HIV-infected patients. Observational studies have documented an association between low plasma vitamin D and HIV infection. Vitamin D status has been shown to be associated with HIV-related disease progression, morbidity and mortality. The objective of this study was to examine the hypothesis that vitamin D status, as assessed by serum 25-hydroxyvitamin D &lt;span>[25(OH)D]&lt;/span> concentrations, are lower in cats with FIV infection compared to healthy control cats. Serum 25(OH)D concentrations were measured in 20 healthy cats, 39 hospitalized ill cats and 59 cats infected with FIV. Cats which were FIV infected had significantly lower 25(OH)D concentrations compared to healthy control cats. Serum 25(OH)D concentrations were not significantly different between FIV-infected cats and hospitalized ill cats. Further investigations are warranted to determine whether vitamin D status influences the prognosis of cats infected with FIV.&lt;/p></description></item><item><title>Children in Uganda have low vitamin D, and lower still if severe malaria</title><link>/posts/children-in-uganda-have-low-vitamin-d-and-lower-still-if-severe-malaria.html</link><pubDate>Wed, 12 Aug 2015 00:00:00 +0000</pubDate><guid>/posts/children-in-uganda-have-low-vitamin-d-and-lower-still-if-severe-malaria.html</guid><description>&lt;h4 id="vitamin-d-insufficiency-is-common-in-ugandan-children-and-is-associated-with-severe-malaria">Vitamin D insufficiency is common in Ugandan children and is associated with severe malaria.&lt;/h4>
&lt;img src="https://d378j1rmrlek7x.cloudfront.net/attachments/jpeg/malaria.jpg" alt="image">
&lt;p>PLoS One. 2014 Dec 3;9(12):e113185. &lt;a href="https://doi.org/10.1371/journal.pone.0113185.">doi: 10.1371/journal.pone.0113185.&lt;/a> eCollection 2014.&lt;/p>
&lt;p>Cusick SE1, Opoka RO2, Lund TC1, John CC1, Polgreen LE3.&lt;/p>
&lt;p>1Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, United States of America.&lt;/p>
&lt;p>2Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, United States of America; Department of Paediatrics, College of Health Sciences, Makerere University, Kampala, Uganda.&lt;/p>
&lt;p>3Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor, University of California Los Angeles, Los Angeles, California, United States of America.&lt;/p></description></item><item><title>200,000 IU restored levels in HIV children having low vitamin D</title><link>/posts/200000-iu-restored-levels-in-hiv-children-having-low-vitamin-d.html</link><pubDate>Thu, 30 Jul 2015 00:00:00 +0000</pubDate><guid>/posts/200000-iu-restored-levels-in-hiv-children-having-low-vitamin-d.html</guid><description>&lt;h4 id="determination-of-optimal-vitamin-d3-dosing-regimens-in-hiv-infected-paediatric-patients-using-a-population-pharmacokinetic-approach">Determination of optimal vitamin D3 dosing regimens in HIV-infected paediatric patients using a population pharmacokinetic approach.&lt;/h4>
&lt;p>Br J Clin Pharmacol. 2014 Nov;78(5):1113-21. &lt;a href="https://doi.org/10.1111/bcp.12433.">doi: 10.1111/bcp.12433.&lt;/a>&lt;/p>
&lt;p>Foissac F1, Meyzer C, Frange P, Chappuy H, Benaboud S, Bouazza N, Friedlander G, Souberbielle JC, Urien S, Blanche S, Tréluyer JM.&lt;/p>
&lt;p>1EA 3620, Sorbonne Paris Cité, Université Paris Descartes, Paris, France; Unité de Recherche Clinique Paris Centre, Assistance Publique Hôpitaux de Paris (APHP), Paris, France.&lt;/p>
&lt;p>AIMS:&lt;/p></description></item><item><title>Vitamin D levels of HIV and non HIV equally restored with 50,000 IU twice a week</title><link>/posts/vitamin-d-levels-of-hiv-and-non-hiv-equally-restored-with-50000-iu-twice-a-week.html</link><pubDate>Fri, 24 Jul 2015 00:00:00 +0000</pubDate><guid>/posts/vitamin-d-levels-of-hiv-and-non-hiv-equally-restored-with-50000-iu-twice-a-week.html</guid><description>&lt;h4 id="success-of-standard-dose-vitamin-d-supplementation-in-treated-human-immunodeficiency-virus-infection">Success of Standard Dose Vitamin D Supplementation in Treated Human Immunodeficiency Virus Infection&lt;/h4>
&lt;p>Open Forum Infect Dis (Spring 2015) 2 (2): &lt;a href="https://doi.org/10.1093/ofid/ofv068">doi: 10.1093/ofid/ofv068&lt;/a>&lt;/p>
&lt;p>Jordan E. Lake1, Risa M. Hoffman1, Chi-Hong Tseng1, Holly M. Wilhalme1, John S. Adams2 and Judith S. Currier1&lt;/p>
&lt;p>1Department of Medicine&lt;/p>
&lt;p>2Department of Orthopaedic Surgery, University of California, Los Angeles&lt;/p>
&lt;p>Correspondence: Jordan E. Lake, MD, MSc, UCLA Department of Medicine, Center for Clinical AIDS Research and Education, 11075 Santa Monica Blvd., Ste. 100, Los Angeles, CA 90025 (&lt;a href="mailto:jlake@mednet.ucla.edu">jlake@mednet.ucla.edu&lt;/a>).&lt;/p></description></item><item><title>Treatment of HIV in youths helped by 7,000 IU of vitamin D for 1 year – RCT</title><link>/posts/treatment-of-hiv-in-youths-helped-by-7000-iu-of-vitamin-d-for-1-year-rct.html</link><pubDate>Wed, 21 Jan 2015 00:00:00 +0000</pubDate><guid>/posts/treatment-of-hiv-in-youths-helped-by-7000-iu-of-vitamin-d-for-1-year-rct.html</guid><description>&lt;nav id="TableOfContents">
 &lt;ul>
 &lt;li>
 &lt;ul>
 &lt;li>
 &lt;ul>
 &lt;li>&lt;a href="#high-dose-vitamin-d3-supplementation-in-children-and-young-adults-with-hiv-a-randomized-placebo-controlled-trial">High-Dose Vitamin D3 Supplementation in Children and Young Adults with HIV: A Randomized, Placebo-Controlled Trial.&lt;/a>&lt;/li>
 &lt;/ul>
 &lt;/li>
 &lt;/ul>
 &lt;/li>
 &lt;/ul>
&lt;/nav>
&lt;hr>
&lt;h4 id="high-dose-vitamin-d3-supplementation-in-children-and-young-adults-with-hiv-a-randomized-placebo-controlled-trial">High-Dose Vitamin D3 Supplementation in Children and Young Adults with HIV: A Randomized, Placebo-Controlled Trial.&lt;/h4>
&lt;p>Pediatr Infect Dis J. 2014 Jul 1.&lt;/p>
&lt;p>Stallings VA1, Schall JI, Hediger ML, Zemel BS, Tuluc F, Dougherty KA, Samuel JL, Rutstein RM.&lt;/p>
&lt;p>BACKGROUND:&lt;/p>
&lt;p>Suboptimal vitamin D status is prevalent in HIV-infected patients and associated with increased risk of disease severity and morbidity. We aimed to determine 12-mo safety and efficacy of daily 7000IU vitamin D3 (vitD3) vs placebo to sustain increased serum 25-hydroxyvitamin D (25(OH)D) and improve immune status in HIV-infected subjects.&lt;/p></description></item><item><title>TB lowers vitamin D, then HIV lowers it even more - 2014</title><link>/posts/tb-lowers-vitamin-d-then-hiv-lowers-it-even-more-2014.html</link><pubDate>Tue, 20 Jan 2015 00:00:00 +0000</pubDate><guid>/posts/tb-lowers-vitamin-d-then-hiv-lowers-it-even-more-2014.html</guid><description>&lt;img src="https://d378j1rmrlek7x.cloudfront.net/attachments/jpeg/tb-dbp.jpg" alt="image">
&lt;img src="https://d378j1rmrlek7x.cloudfront.net/attachments/jpeg/hiv-and-tb.jpg" alt="image">
&lt;img src="https://d378j1rmrlek7x.cloudfront.net/attachments/jpeg/new-tb.jpg" alt="image">
&lt;p>&lt;strong>&lt;i class="fas fa-file-pdf" style="margin-right: 0.3em;">&lt;/i>&lt;a href="https://d378j1rmrlek7x.cloudfront.net/attachments/pdf/anti-inflammatory-and-antimicrobial-actions-of-vitamin-d-in-combating-tb-or-hiv---copy.pdf">Download the PDF from VitaminDWiki.&lt;/a>&lt;/strong>&lt;/p>
&lt;hr>
&lt;p>Vitamin D treats both TB and HIV&lt;/p>
&lt;p>Very low vitamin D leads to many other diseases&lt;/p>
&lt;p>A person with both TB and HIV absolutely, positively should increase their levels of vitamin D.&lt;/p>
&lt;p>It will not only treat both but till decrease the risk of getting other diseases as well&lt;/p>
&lt;p>&lt;strong>See also VitaminDWiki&lt;/strong>&lt;/p>
&lt;p>&lt;a href="/posts/overview-hiv-and-vitamin-d" style="color: red; text-decoration: underline;" title="This post/category does not exist yet: Overview HIV and vitamin D">Overview HIV and vitamin D&lt;/a>&lt;/p></description></item><item><title>Infant HIV, Malaria, and high vitamin D</title><link>/posts/infant-hiv-malaria-and-high-vitamin-d.html</link><pubDate>Sat, 17 Jan 2015 00:00:00 +0000</pubDate><guid>/posts/infant-hiv-malaria-and-high-vitamin-d.html</guid><description>&lt;h4 id="vitamin-d-status-is-associated-with-mortality-morbidity-and-growth-failure-among-a-prospective-cohort-of-hiv-infected-and-hiv-exposed-tanzanian-infants">Vitamin D Status Is Associated with Mortality, Morbidity, and Growth Failure among a Prospective Cohort of HIV-Infected and HIV-Exposed Tanzanian Infants.&lt;/h4>
&lt;p>J Nutr. 2015 Jan;145(1):121-7. &lt;a href="https://doi.org/10.3945/jn.114.201566.">doi: 10.3945/jn.114.201566.&lt;/a> Epub 2014 Nov 12.&lt;/p>
&lt;p>Sudfeld CR 1 &lt;a href="mailto:csudfeld@hsph.harvard.edu">csudfeld@hsph.harvard.edu&lt;/a> , Duggan C2, Aboud S3, Kupka R4, Manji KP5, Kisenge R5, Fawzi WW6.&lt;/p>
&lt;div class="border" style="background-color:#FF9;padding:15px;margin:10px 0;border-radius:5px;width:800px">
&lt;p>High mortality if &amp;gt; 30 ng of vitamin D + HIV + Malaira&lt;/p>
&lt;p>&lt;strong>What caused the vitamin D levels to be so high?&lt;/strong>&lt;/p></description></item><item><title>HIV – lower vitamin D if Black, higher if PI monotherapy</title><link>/posts/hiv-lower-vitamin-d-if-black-higher-if-pi-monotherapy.html</link><pubDate>Wed, 03 Sep 2014 00:00:00 +0000</pubDate><guid>/posts/hiv-lower-vitamin-d-if-black-higher-if-pi-monotherapy.html</guid><description>&lt;h4 id="higher-vitamin-d-levels-in-hiv-infected-out-patients-on-treatment-with-boosted-protease-inhibitor-monotherapy">Higher vitamin D levels in HIV-infected out-patients on treatment with boosted protease inhibitor monotherapy.&lt;/h4>
&lt;p>HIV Med. 2013 Oct;14(9):556-62. &lt;a href="https://doi.org/10.1111/hiv.12049.">doi: 10.1111/hiv.12049.&lt;/a> Epub 2013 Jun 5.&lt;/p>
&lt;p>Cervero M1, Agud JL, Torres R, García-Lacalle C, Alcázar V, Jusdado JJ, Moreno S.&lt;/p>
&lt;div class="border" style="background-color:#FF9;padding:15px;margin:10px 0;border-radius:5px;width:>60%">
&lt;p>97% of Blacks had &amp;lt; 30 ng of vitamin D (11X more than Caucasians)&lt;/p>
&lt;p>boosted PI monotherapy was associated with a lower risk of vitamin D&lt;/p>
&lt;ul>
&lt;li>
&lt;p>&lt;a href="/posts/overview-hiv-and-vitamin-d" style="color: red; text-decoration: underline;" title="This post/category does not exist yet: Overview HIV and vitamin D">Overview HIV and vitamin D&lt;/a>&lt;/p></description></item><item><title>HIV children in UK – Vitamin D recommendations</title><link>/posts/hiv-children-in-uk-vitamin-d-recommendations.html</link><pubDate>Sun, 06 Apr 2014 00:00:00 +0000</pubDate><guid>/posts/hiv-children-in-uk-vitamin-d-recommendations.html</guid><description>&lt;h2 id="from-httpwwwchivaorghttpwwwchivaorg">From &lt;a href="http://www.chiva.org">http://www.chiva.org&lt;/a>&lt;/h2>
&lt;img src="https://d378j1rmrlek7x.cloudfront.net/attachments/jpeg/hiv-children-feb-2014.jpg" alt="image">
&lt;hr>
&lt;p>&lt;strong>&lt;span style="color:#00F;">PDF is attached at the bottom of this page&lt;/span>&lt;/strong>&lt;/p>
&lt;h4 id="vitamindwiki-recommendations">VitaminDWiki Recommendations&lt;/h4>
&lt;p>Do not wait until Autumn and a vitamin D test&lt;/p>
&lt;p>In fact, not vitamin D test is rarely needed.&lt;/p>
&lt;p>Virtually every HIV person is low on vitamin D&lt;/p>
&lt;p>Use a restoring dose of a total of about 300,000 IU over 1 month&lt;/p>
&lt;p>Followed by a maintenace dose of ab least 2,000 IU daily (average)&lt;/p>
&lt;h3 id="see-also-vitamindwiki">See also VitaminDWiki&lt;/h3>
&lt;ul>
&lt;li>
&lt;p>&lt;a href="/posts/overview-hiv-and-vitamin-d" style="color: red; text-decoration: underline;" title="This post/category does not exist yet: Overview HIV and vitamin D">Overview HIV and vitamin D&lt;/a>&lt;/p></description></item><item><title>7000 IU of vitamin D restored most HIV youths to above 32 ng - RCT</title><link>/posts/7000-iu-of-vitamin-d-restored-most-hiv-youths-to-above-32-ng-rct.html</link><pubDate>Fri, 28 Mar 2014 00:00:00 +0000</pubDate><guid>/posts/7000-iu-of-vitamin-d-restored-most-hiv-youths-to-above-32-ng-rct.html</guid><description>&lt;h4 id="safety-and-efficacy-of-high-dose-daily-vitamin-d3-supplementation-in-children-and-young-adults-infected-with-human-immunodeficiency-virus">Safety and Efficacy of High-Dose Daily Vitamin D3 Supplementation in Children and Young Adults Infected With Human Immunodeficiency Virus&lt;/h4>
&lt;p>J Ped Infect Dis (2014) &lt;a href="https://doi.org/10.1093/jpids/piu012">doi: 10.1093/jpids/piu012&lt;/a>&lt;/p>
&lt;p>Kelly A. Dougherty1⇑, Joan I. Schall2, Babette S. Zemel1, Florin Tuluc3, Xiaoling Hou4, Richard M. Rutstein5 and Virginia A. Stallings1&lt;/p>
&lt;p>1Division of Gastroenterology, Hepatology, and Nutrition, University of Pennsylvania Perelman School of Medicine, Children&amp;rsquo;s Hospital of Philadelphia, Pennsylvania&lt;/p>
&lt;p>2Division of Gastroenterology, Hepatology, and Nutrition, Children&amp;rsquo;s Hospital of Philadelphia, Pennsylvania&lt;/p></description></item><item><title>Those with HIV who doubled their vitamin D levels reduced their chance of death by 47 percent</title><link>/posts/those-with-hiv-who-doubled-their-vitamin-d-levels-reduced-their-chance-of-death-by-47-percent.html</link><pubDate>Tue, 22 Oct 2013 00:00:00 +0000</pubDate><guid>/posts/those-with-hiv-who-doubled-their-vitamin-d-levels-reduced-their-chance-of-death-by-47-percent.html</guid><description>&lt;h2 id="paper-was-published-later">Paper was published later&lt;/h2>
&lt;p>&lt;strong>Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons&lt;/strong>&lt;/p>
&lt;p>Journal of Infectious Diseases 10.1093/infdis/jiu074&lt;/p>
&lt;p>Leah Shepherd 1, Jean-Claude Souberbielle 2, Jean-Philippe Bastard 3,4,5, Soraya Fellahi3,4,5, Jaqueline Capeau3,4,5, Joanne Reekie1,6, Peter Reiss7, Anders Blaxhult8, Markus Bickel9, Clifford Leen10,11, Ole Kirk12,13, Jens D. Lundgren12,13, Amanda Mocroft1, Jean-Paul Viard14, On behalf of EuroSIDA in EuroCOORD&lt;/p>
&lt;p>1Department of Infection and Population Health, University College London Medical School, NW3 2PF London, UK&lt;/p></description></item><item><title>HIV – recommend 100,000 IU vitamin D monthly to get levels 30 ng</title><link>/posts/hiv-recommend-100000-iu-vitamin-d-monthly-to-get-levels-30-ng.html</link><pubDate>Fri, 18 Oct 2013 00:00:00 +0000</pubDate><guid>/posts/hiv-recommend-100000-iu-vitamin-d-monthly-to-get-levels-30-ng.html</guid><description>&lt;h3 id="vitamin-d3-supplementation-scheme-in-hiv-infected-patients-based-upon-pharmacokinetic-modelling-of-25-hydroxycholecalciferol">Vitamin D3 supplementation scheme in HIV-infected patients based upon pharmacokinetic modelling of 25-hydroxycholecalciferol.&lt;/h3>
&lt;p>Br J Clin Pharmacol. 2013 May;75(5):1312-20. &lt;a href="https://doi.org/10.1111/bcp.12006.">doi: 10.1111/bcp.12006.&lt;/a>&lt;/p>
&lt;p>Foissac F, Tréluyer JM, Souberbielle JC, Rostane H, Urien S, Viard JP.&lt;/p>
&lt;p>EA 3620 Université Paris Descartes, Sorbonne Paris Cité, France. &lt;a href="mailto:frantz.foissac@cch.aphp.fr">frantz.foissac@cch.aphp.fr&lt;/a>&lt;/p>
&lt;p>AIMS: Vitamin D deficiency is prevalent in HIV-infected patients and has been associated with osteopenia and HIV disease progression. Our aims were to investigate the pharmacokinetics of 25-hydroxycholecalciferol &lt;span>[25(OH)D]&lt;/span>, the effect of antiretroviral treatment (ARV) and others factors that may influence the pharmacokinetics, and to determine a vitamin D3 dosing scheme to reach the 30 ng ml(-1) threshold (defined as 25(OH)D sufficiency).&lt;/p></description></item><item><title>Coronary artery calcification associated with low vitamin D</title><link>/posts/coronary-artery-calcification-associated-with-low-vitamin-d.html</link><pubDate>Tue, 10 Sep 2013 00:00:00 +0000</pubDate><guid>/posts/coronary-artery-calcification-associated-with-low-vitamin-d.html</guid><description>&lt;h4 id="coronary-artery-calcification-33-x-more-likely-if-low-vitd---june-2016">Coronary Artery Calcification 3.3 X more likely if low VitD - June 2016&lt;/h4>
&lt;p>&lt;strong>A Significant Positive Association of Vitamin D Deficiency with Coronary Artery Calcification among Middle-aged Men: For the ERA JUMP Study.&lt;/strong>&lt;/p>
&lt;p>J Am Coll Nutr. 2016 Jun 17:1-7. &lt;span>[Epub ahead of print]&lt;/span>&lt;/p>
&lt;p>Lee S1, Ahuja V2, Masaki K3, Evans RW2, Barinas-Mitchell EJ2, Ueshima H4, Shin C5, Choo J6, Hassen L2, Edmundowicz D7, Kuller LH2, Willcox B3, Sekikawa A2,4.&lt;/p></description></item><item><title>HIV increases Calcium in soft tissues and reduces Calcium in bones</title><link>/posts/hiv-increases-calcium-in-soft-tissues-and-reduces-calcium-in-bones.html</link><pubDate>Wed, 28 Aug 2013 00:00:00 +0000</pubDate><guid>/posts/hiv-increases-calcium-in-soft-tissues-and-reduces-calcium-in-bones.html</guid><description>&lt;h3 id="inverse-correlation-between-vascular-calcification-and-bone-mineral-density-in-human-immunodeficiency-virus-infected-patients">Inverse Correlation Between Vascular Calcification and Bone Mineral Density in Human Immunodeficiency Virus-Infected Patients&lt;/h3>
&lt;p>Calcified Tissue International, August 2013&lt;/p>
&lt;p>Antonio Bellasi,&lt;/p>
&lt;p>Stefano Zona,&lt;/p>
&lt;p>Gabriella Orlando,&lt;/p>
&lt;p>Federica Carli,&lt;/p>
&lt;p>Guido Ligabue,&lt;/p>
&lt;p>Vincenzo Rochira,&lt;/p>
&lt;p>Antonella Santoro,&lt;/p>
&lt;p>Cristina Mussini,&lt;/p>
&lt;p>Giovanni Guaraldi, &lt;a href="mailto:giovanni.guaraldi@unimore.it">giovanni.guaraldi@unimore.it&lt;/a>&lt;/p>
&lt;p>Paolo Raggi&lt;/p>
&lt;p>HIV-infected individuals suffer from accelerated aging, which manifests as premature cardiovascular and bone disease. However, little is known of the association of these two disorders in the HIV population. Our objective was to investigate the association between a marker of atherosclerosis (coronary artery calcium &lt;span>[CAC]&lt;/span>) and low bone mineral density (BMD) in a cross-sectional cohort of HIV-infected patients. The study was conducted at the University of Modena and Reggio Emilia, Italy. A total of 636 consecutive middle-aged, HIV-infected subjects were recruited between January 2006 and December 2010. All patients underwent CAC and BMD assessment. Patients were categorized according to a CAC score &amp;lt;100 or &amp;gt;100 units based on previous literature that identified this cut-point as a marker of increased risk.&lt;/p></description></item><item><title>HIV interactions with low Vitamin D</title><link>/posts/hiv-interactions-with-low-vitamin-d.html</link><pubDate>Sat, 18 May 2013 00:00:00 +0000</pubDate><guid>/posts/hiv-interactions-with-low-vitamin-d.html</guid><description>&lt;h3 id="vitamin-d-deficiency-in-hiv-infection-an-underestimated-and-undertreated-epidemic">Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic&lt;/h3>
&lt;p>European Review for Medical and Pharmacological Sciences&lt;/p>
&lt;p>M.R. P\NZONE, M. D\ ROSA, M. MAIAGUARNERA, G. MADEDDU, E. FOCA, G. CECCARELL, G. D&amp;rsquo;ETTORRE, V. VULLO, R. F\S\CHELLA, B. CACOPARDO, G. NUNNAR\1,7&lt;/p>
&lt;p>Corresponding Author: Giuseppe Nunnari, MD; e-mail: &lt;a href="mailto:gnunnari@hotmail.com">gnunnari@hotmail.com&lt;/a>&lt;/p>
&lt;p>Hypovitaminosis D is a very common disorder, regarding both Western and developing countries. A growing amount of data over the last years have shown vitamin D deficiency to be high prevalent among HIV-positive subjects. In addition to &amp;ldquo;classic&amp;rdquo; risk factors, such as female sex, low dietary intake, dark skin pigmentation and low sun exposure, HlV-related factors, including immune activation and anti-retroviral adverse effects, may affect vitamin D status. Even if both protease inhibitors and non-nucleoside reverse transcriptase inhibitors have been associated with low vitamin D levels, available evidences have failed to univocally associate hypovitaminosis D with specific antiretroviral class effects.&lt;/p></description></item><item><title>HIV inflammation markers associated with vitamin D less than 10 ng</title><link>/posts/hiv-inflammation-markers-associated-with-vitamin-d-less-than-10-ng.html</link><pubDate>Mon, 07 Jan 2013 00:00:00 +0000</pubDate><guid>/posts/hiv-inflammation-markers-associated-with-vitamin-d-less-than-10-ng.html</guid><description/></item><item><title>HIV associated with low vitamin D and high C-reactive protein</title><link>/posts/hiv-associated-with-low-vitamin-d-and-high-c-reactive-protein.html</link><pubDate>Mon, 12 Nov 2012 00:00:00 +0000</pubDate><guid>/posts/hiv-associated-with-low-vitamin-d-and-high-c-reactive-protein.html</guid><description>&lt;h1 id="serum-25-hydroxyvitamin-d-levels-and-c-reactive-protein-in-persons-with-human-immunodeficiency-virus-infection">Serum 25-hydroxyvitamin D levels and C-reactive protein in persons with Human Immunodeficiency Virus infection.&lt;/h1>
&lt;p>AIDS Res Hum Retroviruses. 2012 Sep 24.&lt;/p>
&lt;p>Poudel-Tandukar K, Poudel KC, Jimba M, Kobayashi J, Johnson CA, Palmer PH.&lt;/p>
&lt;p>Waseda University, Waseda Institute for Advanced Study, 1-6-1 Nishi-waseda, Shinjuku-ku, Tokyo, Japan, 1698050; &lt;a href="mailto:kkpoudel@hotmail.com">kkpoudel@hotmail.com&lt;/a>.&lt;/p>
&lt;p>Human Immunodeficiency Virus (HIV) infection has been frequently associated with vitamin D deficiency as well as chronic inflammatory response. We tested the hypothesis of an independent relationship between serum concentrations of 25-hydroxyvitamin D (25&lt;span>[OH]&lt;/span>D) and high-sensitivity C-reactive protein (CRP) in a cohort of HIV-positive people. A cross-sectional survey was conducted among 316 HIV-positive people (181 men and 135 women) aged 16 to 60 years residing in the Kathmandu Valley, &lt;strong>Nepal&lt;/strong> . Serum high-sensitivity CRP concentrations and serum 25(OH)D levels were measured by the latex agglutination nephelometry method and the competitive protein-binding assay, respectively. The relationship between serum CRP concentrations and 25(OH)D serum level were assessed using multiple logistic regression analysis with adjustment of potential cardiovascular and HIV-related factors. The proportion of participants with 25(OH)D serum level of &amp;lt;20ng/mL, 20-30ng/mL, and &amp;gt;30ng/mL were 83.2%, 15.5%, and 1.3%, respectively. The mean 25(OH)D serum level in men and women were 15.3ng/mL and 14.4ng/mL, respectively.&lt;/p></description></item><item><title>HIV patients having EFC therapy were 3X more likely to have low vitamin D levels</title><link>/posts/hiv-patients-having-efc-therapy-were-3x-more-likely-to-have-low-vitamin-d-levels.html</link><pubDate>Sat, 29 Sep 2012 00:00:00 +0000</pubDate><guid>/posts/hiv-patients-having-efc-therapy-were-3x-more-likely-to-have-low-vitamin-d-levels.html</guid><description>&lt;h1 id="vitamin-d-insufficiency-and-deficiency-among-hiv-1-infected-patients-in-a-tropical-setting">Vitamin D Insufficiency and Deficiency among HIV-1-Infected Patients in a Tropical Setting&lt;/h1>
&lt;p>Journal of the International Assoc. of Physicians in AIDS Care SeptOct 2012 vol. 11 no. 5 305-310&lt;/p>
&lt;p>Surasak Wiboonchutikul, MD1&lt;/p>
&lt;p>Somnuek Sungkanuparph, MD1 &lt;a href="mailto:somnuek.sun@mahidol.ac.th">somnuek.sun@mahidol.ac.th&lt;/a>&lt;/p>
&lt;p>Sasisopin Kiertiburanakul, MD, MHS1&lt;/p>
&lt;p>La-or Chailurkit, PhD1&lt;/p>
&lt;p>Angkana Charoenyingwattana, PharmD2&lt;/p>
&lt;p>Wittaya Wangsomboonsiri, MD3&lt;/p>
&lt;p>Wasun Chantratita, PhD1&lt;/p>
&lt;p>Boonsong Ongphiphadhanakul, MD1&lt;/p>
&lt;p>1 Ramathibodi Hospital, Mahidol University, Bangkok, Thailand&lt;/p>
&lt;p>2 Pharmacogenomics Project Under Collaboration Between Thailand Center of Excellence for Life Sciences, Mahidol University, Bangkok, Thailand&lt;/p></description></item><item><title>1700 IU daily average restored HIV vitamin D levels (50000 monthly)</title><link>/posts/1700-iu-daily-average-restored-hiv-vitamin-d-levels-50000-monthly.html</link><pubDate>Thu, 30 Aug 2012 00:00:00 +0000</pubDate><guid>/posts/1700-iu-daily-average-restored-hiv-vitamin-d-levels-50000-monthly.html</guid><description>&lt;h3 id="serum-25-hydroxyvitamin-d-response-to-vitamin-d3-supplementation-50000-iu-monthly-in-youth-with-hiv-1-infection">Serum 25-Hydroxyvitamin D Response to Vitamin D3 Supplementation 50,000 IU Monthly in Youth with HIV-1 Infection&lt;/h3>
&lt;p>The Journal of Clinical Endocrinology &amp;amp; Metabolism August 29, 2012 jc.2012-2600&lt;/p>
&lt;p>Peter L. Havens, Kathleen Mulligan, Rohan Hazra, Patricia Flynn, Brandy Rutledge, Marta D. Van Loan, Jorge Lujan-Zilbermann, Bill G. Kapogiannis, Craig M. Wilson, Charles B. Stephensen and the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 063 Study Team&lt;/p>
&lt;p>Children’s Research Institute (P.L.H.), Medical College of Wisconsin, Children’s Hospital of Wisconsin, Milwaukee, Wisconsin 53201; University of California at San Francisco (K.M.), San Francisco, California 94110; Eunice Kennedy Shriver National Institute of Child Health and Human Development (R.H., B.G.K.), Bethesda, Maryland 20892; St. Jude Children’s Research Hospital (P.F.), Memphis, Tennessee 38105; Westat (B.R.), Rockville, Maryland 20850; United States Department of Agriculture Agricultural Research Service (M.D.V.L., C.B.S.), Western Human Nutrition Research Center, Davis, California 95616; University of South Florida College of Medicine (J.L.-Z.), Tampa, Florida 33606; and University of Alabama at Birmingham (C.M.W.), Birmingham, Alabama 35294&lt;/p></description></item><item><title>HIV leads to low vitamin D which leads to osteoporosis – a growing problem</title><link>/posts/hiv-leads-to-low-vitamin-d-which-leads-to-osteoporosis-a-growing-problem.html</link><pubDate>Fri, 24 Aug 2012 00:00:00 +0000</pubDate><guid>/posts/hiv-leads-to-low-vitamin-d-which-leads-to-osteoporosis-a-growing-problem.html</guid><description>&lt;h4 id="osteoporosis-in-persons-with-hiv-a-future-epidemic">Osteoporosis in persons with HIV: a future epidemic?&lt;/h4>
&lt;p>J La State Med Soc. 2012 May-Jun;164(3):127-30.&lt;/p>
&lt;p>Clark R.&lt;/p>
&lt;p>Louisiana State University Health Sciences Center, New Orleans, USA.&lt;/p>
&lt;p>Given the aging of the American population with human immunodeficiency virus (HIV) and the high prevalence of suboptimal 25(OH)D (vitamin D) levels, osteoporosis is likely to be a growing concern among clinicians caring for this population. HIV infection has been shown to be a strong predictor for an abnormal dual X-ray absorptionmetry testing and is potentially a risk for fractures at older ages. This paper reviews management issues for osteoporosis specific to the population with HIV, including both prevention and treatment strategies.&lt;/p></description></item><item><title>Blacks with HIV were 3.5X more likely to be vitamin D deficient than whites</title><link>/posts/blacks-with-hiv-were-35x-more-likely-to-be-vitamin-d-deficient-than-whites.html</link><pubDate>Mon, 23 Jul 2012 00:00:00 +0000</pubDate><guid>/posts/blacks-with-hiv-were-35x-more-likely-to-be-vitamin-d-deficient-than-whites.html</guid><description>&lt;h1 id="risk-factors-for-vitamin-d-deficiency-in-hiv-infected-patients-in-the-south-central-united-states">Risk factors for vitamin D deficiency in HIV-infected patients in the south central United States.&lt;/h1>
&lt;p>AIDS Res Hum Retroviruses. 2012 May;28(5):454-9. Epub 2011 Oct 19.&lt;/p>
&lt;p>Crutchley RD, Gathe J Jr, Mayberry C, Trieu A, Abughosh S, Garey KW.&lt;/p>
&lt;p>University of Houston, College of Pharmacy, Department of Clinical Sciences and Administration, 1441 Moursund Street, Houston, TX 77030, USA. &lt;a href="mailto:rdcrutchley@uh.edu">rdcrutchley@uh.edu&lt;/a>&lt;/p>
&lt;p>We evaluated the prevalence of serum 25-hydroxyvitamin D &lt;span>[25(OH)D]&lt;/span> deficiency and the risk factors for vitamin D deficiency in HIV-infected patients in the South-Central United States. The study consisted of a cross-sectional assessment of vitamin D levels in HIV-infected patients receiving routine clinical care from a private practice in Houston, Texas (latitude 29°N). Vitamin D deficiency was defined as 25(OH)D less than 20?ng/ml (&amp;lt;50?nmol/liter). Two-hundred enrolled patients were surveyed with a vitamin D questionnaire to determine daily supplemental vitamin D intake, dietary vitamin D intake, and average sunlight exposure (minutes/day). Multivariate logistic regression analysis was used to determine significant risk factors for vitamin D deficiency. Median 25(OH)D was 15.5?ng/ml (interquartile range 10.9-24.6) for the total population (n=200).&lt;/p></description></item></channel></rss>